Constipation · people with CKD
Summary of findings: Sevelamer may leads to higher constipation compared with placebo/usual care (low certainty).
1 finding from 1 review
Serum phosphate level · people with CKD
1 finding from 1 review
Coronary artery calcification score · people with CKD
1 finding from 1 review
Death (all causes) · people with CKD
It is very uncertain whether summary of findings: Lanthanum changes death (all causes) compared with placebo/usual care (very low certainty).
1 finding from 1 review
Death · chronic non‐hypovolaemic hypotonic hyponatraemia
It is very uncertain whether vasopressin receptor antagonists changes death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Health‐related quality of life ( · chronic non‐hypovolaemic hypotonic hyponatraemia
1 finding from 1 review
Length of hospital stay · chronic non‐hypovolaemic hypotonic hyponatraemia
1 finding from 1 review
Cognitive function · chronic non‐hypovolaemic hypotonic hyponatraemia
1 finding from 1 review
Change from baseline in serum sodium concentration · chronic non‐hypovolaemic hypotonic hyponatraemia
1 finding from 1 review
Serum sodium concentration (response) · chronic non‐hypovolaemic hypotonic hyponatraemia
Vasopressin receptor antagonists probably leads to higher serum sodium concentration (response) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Rapid sodium increase · chronic non‐hypovolaemic hypotonic hyponatraemia
Vasopressin receptor antagonists probably leads to higher rapid sodium increase compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
AKI within 30 days of surgery · adults with normal kidney function undergoing surgery
It is very uncertain whether nonsteroidal anti‐inflammatory drugs (NSAIDs) changes AKI within 30 days of surgery compared with placebo or no treatment (very low certainty).
1 finding from 1 review
SCr increase within 30 days of surgery · adults with normal kidney function undergoing surgery
1 finding from 1 review
RRT within 30 days of surgery · adults with normal kidney function undergoing surgery
It is very uncertain whether nonsteroidal anti‐inflammatory drugs (NSAIDs) changes RRT within 30 days of surgery compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Death (all causes) · adults with normal kidney function undergoing surgery
It is very uncertain whether nonsteroidal anti‐inflammatory drugs (NSAIDs) changes death (all causes) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Length of hospital stay · adults with normal kidney function undergoing surgery
It is very uncertain whether nonsteroidal anti‐inflammatory drugs (NSAIDs) changes length of hospital stay compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Loss of patency by 12 months · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in loss of patency: compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).
1 finding from 1 review